Stock analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 0.8 %
NASDAQ EVOK opened at $3.87 on Monday. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $18.60. The company has a fifty day simple moving average of $5.52 and a 200 day simple moving average of $6.14. The company has a market cap of $33.27 million, a P/E ratio of -2.11 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Business Services Stocks Investing
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- How to Buy Cheap Stocks Step by Step
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- EV Stocks and How to Profit from Them
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
